Regeneron reports better-than-expected third-quarter results, beating earnings and revenue estimates, driven by strong Eylea HD, Dupixent and Libtayo sales.

With the recent EU approval in chronic obstructive pulmonary disease, we now model $21 billion in peak Dupixent sales by 2029. While the partnership with Sanofi for new pipeline products has been ...

People over the age of 50 who have severe mental illness are more likely than the general population to experience fragility fractures but may be less likely to get a diagnosis for osteoporosis ...

U.S. drugmaker Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter profit and revenue on Thursday, driven ...

Dupixent (dupilumab ... including atopic dermatitis in children, some forms of chronic obstructive pulmonary disease (COPD), and various conditions leading to urticaria (hives).

Despite disappointing third-quarter results for Regeneron’s high-dose Eylea injection, analysts continued to be cautiously ...

Regeneron should weather the Eylea biosimilar launch storm and continue to deliver long-term shareholder value. See why REGN ...

With increasing chronic diseases, demand for personalized medicines, and adoption of AI, the biotech market is booming.

Multinational pharmaceutical and medical equipment companies will bring a variety of innovative medical solutions that ...

Dupixent is already approved to treat ... The drug is also being tested in some forms of chronic obstructive pulmonary disease (COPD) and various conditions leading to urticaria (hives), although ...